Side Effect Management
An Expert Breaks Down Lymphedema Following Cancer Care
Dr. Sheri Yolanda Prentiss discusses the importance of seeking early intervention to detect lymphedema following cancer care.
PROSTOX May Predict Urinary Side Effects Post Prostate Cancer Radiation
A test to identify higher risk of developing urinary side effects after radiation in patients with prostate cancer was confirmed by data from a new study.
Early Intervention and Screening Prevents Lymphedema After Cancer
Dr. Sheri Yolanda Prentiss discusses lymphedema as a result of cancer treatment and shares resources that exist for patients coping with this condition.
Raising Awareness for Lymphedema Following a Cancer Diagnosis
Dr. Sheri Yolanda Prentiss explores the challenges patients face in accessing lymphedema compression garments following cancer treatment.
Survey Findings Reveal Financial Challenges in Patients with Cancer
Among patients with cancer, high out-of-pocket costs were found to impact access to health care, adherence to medication, as well as quality of life.
Why Physical Therapy Should Begin at the Time of a Cancer Diagnosis
CURE spoke with Leslie Waltke about the importance of physical therapy during a cancer journey.
Childhood Cancer Survivors May Experience Sooner Aging-Related Disease
Researchers have found childhood cancer survivors are at risk of experiencing onset of aging-related disease 17.7 years sooner than the general population.
Itolizumab Shows Long-Term Treatment Benefits in Acute GVHD
Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant benefits in long-term outcomes.
Dr. Sheri Prentiss on Steps for Lymphedema Screening in Breast Cancer
Dr. Sheri Prentiss discusses what steps patients can take to ensure they're being screened for lymphedema prior to starting their breast cancer treatment.
Orca-T Doubles Graft-Versus-Host Disease-Free Survival in Leukemia
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.
First Patient Dosed in Trial for Chemotherapy-Induced Neuropathic Pain
The first patient has been dosed in a phase 2b trial evaluating the first-in-class agent Halneuron for those with neuropathic pain following chemotherapy.
Expert Explains the Side Effects of Ordspono in R/R Follicular Lymphoma
Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.
FDA Approves Biosimilars for Cancer-Related Skeletal Events
The FDA has approved Stoboclo and Osenvelt to address skeletal issues faced by patients with cancer.
Expert Explains Safety of Krazati Regimen For Treating Colorectal Cancer
Krazati plus Erbitux is well tolerated in KRAS G12C-mutant metastatic colorectal cancer, with manageable side effects and less immune suppression.
Immune Checkpoint Inhibitors For Cancer Associated With Psoriasis Risk
Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a risk of new onset psoriasis.
Fractionated Reirradiation is Safe and Feasible in High-Grade Glioma
Fractionated reirradiation is safe and feasible, suggesting higher reirradiation dose may be feasible in patients with recurrent high-grade glioma.
A Study Investigates If CAR T Therapy Directly Causes Secondary Malignancies
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
What Patients With Breast Cancer Need to Know About Itovebi and Blood Sugar
An expert explained a potential side effect associated with treatment consisting of Itovebi for breast cancer.
Treating Lymphedema with a Simple Trinket
Buying a pretty bracelet was healing because it let me look at my lymphedema in a new light.
GAP Triplet May Be Less Safe Than Doublet Chemo in Biliary Tract Cancer
An expert explains that the GAP regimen did not improve overall survival in advanced biliary tract cancer versus the doublet and increased severe side effects.
Brukinsa Shows Favorable Safety Profile Over Imbruvica in CLL
Researchers have found Brukinsa to be a potentially safer alternative for patients with chronic lymphocytic leukemia.
How Patients With Cancer Can Avoid Counterfeit Therapeutics Online
Dr. Megan Menon explains how patients can verify the authenticity of online prescription purchases for their cancer treatment.
What Patients With Cancer Need to Know About Counterfeit Drugs Risk
It’s a $4 billion a year industry that includes fraudulent anti-cancer drugs and opioid medications. Here is what patients need to know about the risk of counterfeit drugs.
An Expert Breaks Down the Effect of Diabetes on Urothelial Cancer Treatment
Dr. Petros Grivas discusses what precautions should be considered when treating patients with advanced urothelial carcinoma who have diabetes.
Padcev May Be Safe in Older Patients With Bladder Cancer
Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.
Facing Cancer Together: Jim and Melanie’s Patient-Caregiver Story
Diagnosed with stage 3B lung cancer in 2018, I joined a support group where I met Jim and Melanie, and learned about Jim's sarcoma diagnosis.
Breaking Down the FDA Labeling Update of Xeloda and 5-FU in Cancer Care
The FDA has updated the product labeling for Xeloda and 5-FU to highlight the risks associated with dihydropyrimidine dehydrogenase deficiency.
An Expert Breaks Down What DPD Is and Labeling Updates From The FDA
Dr. Gabriel A. Brooks discusses the recent FDA product labeling update for Xeloda and 5-FU which aims to highlight risks associated with DPD deficiency.
Tagrisso Associated With Cardiac Side Effects in Non-Small Cell Lung Cancer
Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events and reduced overall survival.
Weight Gain Measurements May Be Underreported in ALK+ NSCLC Trials
Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive management of this side effect.
